Citicoline Injection 1g/4ml with GMP Grade

• Powder: No
• Customized: Customized
• Certification: GMP
• Suitable for: Elderly, Children, Adult
• State: Liquid
• Purity: >99%
• Model NO.: 1g/4ml
• Storage: Normal Temperature
• Transport Package: Box
• Specification: 1g/4ml
• Trademark: Without
• Origin: China
• Production Capacity: 100000 Pieces

Product Description

Product Description

 

PHARMACOLOGICAL PROPERTIES:
PHARMACODINAMICS
Citicoline, being the precursor of key ultrastructural components of a cellular membrane (mainly phospholipids), possesses wide range of activities, promotes restoration of the damaged cell membranes, inhibits action of phospholipases, what prevents excessive formation of free radicals and destruction of cells, affects the mechanisms of apoptosis. In the acute period of stroke it reduces the volume of damaged tissue, improves cholinergic transmition. In head injury it reduces duration of a post-traumatic coma and intensity of neurologic symptoms. Citicoline improves observed during hypoxia symptoms, such as memory impairment, emotional liability, lack of initiative, difficulties at conducting of daily actions and self-service. The drug product does not influence breath, pulse and arterial pressure; therefore long treatment is possible. 

PHARMACOKINETICS
As Citicoline is natural compound which is found in organism, it is impossible to provide classical pharmacokinetic research in connection with complexity of quantitative analysis of exogenous and endogenous 
Citicoline.

INDICATIONS:
1. Disturbance of consciousness associated with head injury or brain surgery.
2. Promotion of rehabilitation of the upper extremities in patients with hemiplegia following cerebral apoplexy.
3. Treatment in combination with anticholinergics in the following cases of parkinson's disease, in which tremor is especially severe:
- Cases in which adverse reactions have developed under treatment with L-DOPA.
- Cases in which the administration of L-DOPA is difficult because of laparotomy or complication.
- Cases in which L-DOPA is ineffective.
4.Concomitant therapy with protease inhibitors in the treatment of the following diseases:
- Acute pancreatitis.
- Acute exacerbation of chronic recurrent pancreatitis.
- Acute pancreatitis after surgery.

 

Product name	Citicoline injection
specification	1g/4ml
Packaging	5 ampoules/tray/box
Storage	Sealed and stored below 25ºC.
Validity	36 months

Company Profile

 

Tenas takes "quality leading, technology leading, cost leading and service leading" as its business philosophy. "Make good medicine in the world, and make human health more guaranteed!"
Tenas is willing to provide you with a wide variety, complete specifications and excellent quality of Pharmaceutical product; And is willing to sincerely join hands with you to make contributions to the cause of human health!